CAR-T comes of age?
Thursday, October 14, at 1:00 p.m. ET / 10:00 a.m. PT
It’s been almost a decade since the release of the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it.
Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that?
STAT gathers experts to look ahead.
- Adam Feuerstein, senior writer, biotech, STAT (moderator)
- Anshul Mangal, president, Project Farma and Precision ADVANCE (sponsor speaker)